Different transcriptional profiling between senescent and non-senescent human coronary artery endothelial cells (HCAECs) by Omeprazole and Lansoprazole treatment

Recent evidence suggests that high dose and/or long term use of proton pump inhibitors (PPIs) may increase the risk of adverse cardiovascular events in older patients, but mechanisms underlying these detrimental effects are not known. Taking into account that the senescent endothelial cells have been implicated in the genesis or promotion of age-related cardiovascular disease, we hypothesized an active role of PPIs in senescent cells. The aim of this study is to investigate the changes in gene expression occurring in senescent and non-senescent human coronary artery endothelial cells (HCAECs) following Omeprazole (OPZ) or Lansoprazole (LPZ) treatment. Here, we show that atherogenic response is among the most regulated processes in PPI-treated HCAECs. PPIs induced down-regulation of anti-atherogenic chemokines (CXCL11, CXCL12 and CX3CL1) in senescent but not in non-senescent cells, while the same chemokines were up-regulated in untreated senescent cells. These findings support the hypothesis that up-regulated anti-atherogenic chemokines may represent a defensive mechanism against atherosclerosis during cellular senescence, and suggest that PPIs could activate pro-atherogenic pathways by changing the secretory phenotype of senescent HCAECs. Moreover, the genes coding for fatty acid binding protein 4 (FABP4) and piezo-type mechanosensitive ion channel component 2 (PIEZO2) were modulated by PPIs treatment with respect to untreated cells. In conclusions, our results show that long-term and high dose use of PPI could change the secretory phenotype of senescent cells, suggesting one of the potential mechanisms by which use of PPI can increase adverse outcomes in older subjects.

[1]  R. Busse,et al.  Endothelial aging. , 2005, Cardiovascular research.

[2]  J. Veerkamp,et al.  New insights into the structure and function of fatty acid-binding proteins , 2002, Cellular and Molecular Life Sciences CMLS.

[3]  Karen L. Mohlke,et al.  INK4/ARF Transcript Expression Is Associated with Chromosome 9p21 Variants Linked to Atherosclerosis , 2009, PloS one.

[4]  G. Der.  An overview of proton pump inhibitors. , 2003, Gastroenterology nursing : the official journal of the Society of Gastroenterology Nurses and Associates.

[5]  T. Strandberg,et al.  Use of proton pump inhibitors and mortality among institutionalized older people. , 2010, Archives of internal medicine.

[6]  S. Anton,et al.  Molecular inflammation: Underpinnings of aging and age-related diseases , 2009, Ageing Research Reviews.

[7]  T. Ueland,et al.  Heart failure biomarkers: focus on interleukin-1 receptor-like 1-based blood tests. , 2012, Drugs of today.

[8]  S. Lowe,et al.  Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas , 2011, Nature.

[9]  J. Campisi.  Aging, cellular senescence, and cancer. , 2013, Annual review of physiology.

[10]  S. Bandinelli,et al.  Proton pump inhibitors and risk of 1-year mortality and rehospitalization in older patients discharged from acute care hospitals. , 2013, JAMA internal medicine.

[11]  M. Bennett,et al.  Endogenous p53 Protects Vascular Smooth Muscle Cells From Apoptosis and Reduces Atherosclerosis in ApoE Knockout Mice , 2004, Circulation research.

[12]  B. Staels,et al.  PPAR alpha inhibits vascular smooth muscle cell proliferation underlying intimal hyperplasia by inducing the tumor suppressor p16INK4a. , 2005, The Journal of clinical investigation.

[13]  Amy Linsky,et al.  Proton pump inhibitors and risk for recurrent Clostridium difficile infection. , 2010, Archives of internal medicine.

[14]  A. Khanna.  Enhanced susceptibility of cyclin kinase inhibitor p21 knockout mice to high fat diet induced atherosclerosis , 2009, Journal of Biomedical Science.

[15]  S. Lowe,et al.  Senescence of Activated Stellate Cells Limits Liver Fibrosis , 2008, Cell.

[16]  P. Siersema,et al.  Proton pump inhibitor therapy predisposes to community‐acquired Streptococcus pneumoniae pneumonia , 2012, Alimentary pharmacology & therapeutics.

[17]  Josef Coresh,et al.  Proton Pump Inhibitor Use and the Risk of Chronic Kidney Disease. , 2016, JAMA internal medicine.

[18]  N. Shah,et al.  Proton pump inhibitors and vascular function: A prospective cross-over pilot study , 2015, Vascular medicine.

[19]  R. Antonelli Incalzi,et al.  Proton Pump Inhibitors and Functional Decline in Older Adults Discharged From Acute Care Hospitals , 2014, Journal of the American Geriatrics Society.

[20]  J. Erusalimsky.  Vascular endothelial senescence: from mechanisms to pathophysiology. , 2009, Journal of applied physiology.

[21]  Hailing Qiao,et al.  Pharmacokinetics of lansoprazole in Chinese healthy subjects in relation to CYP2C19 genotypes. , 2004, Acta pharmacologica Sinica.

[22]  P. Poole‐Wilson,et al.  Pathogenesis of Congestive State in Chronic Obstructive Pulmonary Disease: Studies of Body Water and Sodium, Renal Function, Hemodynamics, and Plasma Hormones During Edema and After Recovery , 1992, Circulation.

[23]  Kwang-Hyeon Liu,et al.  Stereoselective inhibition of cytochrome P450 forms by lansoprazole and omeprazole in vitro , 2005, Xenobiotica; the fate of foreign compounds in biological systems.

[24]  J. Campisi,et al.  Four faces of cellular senescence , 2011, The Journal of cell biology.

[25]  P. Gallagher,et al.  Piezo Proteins: Regulators of Mechanosensation and Other Cellular Processes* , 2014, The Journal of Biological Chemistry.

[26]  Shu Chien,et al.  Piezo1, a mechanically activated ion channel, is required for vascular development in mice , 2014, Proceedings of the National Academy of Sciences.

[27]  M. Rudling,et al.  Activation of VPAC1 receptors aggravates early atherosclerosis in hypercholesterolemic apolipoprotein E-deficient mice. , 2010, Biochemical and biophysical research communications.

[28]  R. Vasan,et al.  Soluble ST2 predicts elevated SBP in the community , 2013, Journal of hypertension.

[29]  N. Plant,et al.  Fatty acid binding proteins: tissue-specific functions in health and disease , 2014, Current opinion in clinical nutrition and metabolic care.

[30]  T. Maciag,et al.  Serial propagation of human endothelial cells in vitro , 1981, The Journal of cell biology.

[31]  D. McCarthy.  Adverse effects of proton pump inhibitor drugs: clues and conclusions , 2010, Current opinion in gastroenterology.

[32]  C. Lawson,et al.  ICAM-1 signaling in endothelial cells , 2009, Pharmacological reports : PR.

[33]  N. Shah,et al.  Unexpected Effect of Proton Pump Inhibitors: Elevation of the Cardiovascular Risk Factor Asymmetric Dimethylarginine , 2013, Circulation.

[34]  J. Campisi,et al.  Protocols to detect senescence-associated beta-galactosidase (SA-βgal) activity, a biomarker of senescent cells in culture and in vivo , 2009, Nature Protocols.

[35]  J. Al Suwaidi,et al.  Endothelial Dysfunction: Cardiovascular Risk Factors, Therapy, and Outcome , 2005, Vascular health and risk management.

[36]  Stefanie Dimmeler,et al.  Antioxidants Inhibit Nuclear Export of Telomerase Reverse Transcriptase and Delay Replicative Senescence of Endothelial Cells , 2004, Circulation research.

[37]  J. Campisi,et al.  Cellular senescence and the senescent secretory phenotype: therapeutic opportunities. , 2013, The Journal of clinical investigation.

[38]  K. Schmid,et al.  GABAB Receptors Expressed in Human Aortic Endothelial Cells Mediate Intracellular Calcium Concentration Regulation and Endothelial Nitric Oxide Synthase Translocation , 2014, BioMed research international.

[39]  T. Ince,et al.  Fatty acid binding protein 4 is a target of VEGF and a regulator of cell proliferation in endothelial cells , 2009, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[40]  R. Andriantsitohaina,et al.  Age-related endothelial dysfunction : potential implications for pharmacotherapy. , 2003, Drugs & aging.

[41]  Jean-Fred Fontaine,et al.  CXCL5 limits macrophage foam cell formation in atherosclerosis. , 2013, The Journal of clinical investigation.

[42]  J. Plutzky,et al.  Endothelial cell-fatty acid binding protein 4 promotes angiogenesis: role of stem cell factor/c-kit pathway , 2012, Angiogenesis.

[43]  A. Lerman,et al.  Intact and altered endothelium in regulation of vasomotion. , 1992, Circulation.

[44]  J. Cooke,et al.  Proton Pump Inhibitors Accelerate Endothelial Senescence. , 2016, Circulation research.

[45]  U. Laufs,et al.  Heart-rate reduction by If-channel inhibition with ivabradine restores collateral artery growth in hypercholesterolemic atherosclerosis. , 2012, European heart journal.

[46]  F. Kiessling,et al.  CXCL12 Promotes the Stabilization of Atherosclerotic Lesions Mediated by Smooth Muscle Progenitor Cells in Apoe-Deficient Mice , 2013, Arteriosclerosis, thrombosis, and vascular biology.

[47]  D. Kurz,et al.  Cellular senescence in vivo: Its relevance in ageing and cardiovascular disease , 2005, Experimental Gerontology.

[48]  R. McEver.  Selectins: initiators of leucocyte adhesion and signalling at the vascular wall. , 2015, Cardiovascular research.

[49]  Nigam H. Shah,et al.  Proton Pump Inhibitor Usage and the Risk of Myocardial Infarction in the General Population , 2015, PloS one.

[50]  C. Afonso,et al.  Slow, spontaneous degradation of lansoprazole, omeprazole and pantoprazole tablets: isolation and structural characterization of the toxic antioxidants 3H-benzimidazole-2-thiones. , 2013, Pharmazie.

[51]  D. Baker,et al.  Cellular senescence in aging and age-related disease: from mechanisms to therapy , 2015, Nature Medicine.